Clinical Trial Update: A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) [Phase 2, Phase 3]

View source ↗

Summary

A multi-center randomized trial evaluating AK104 with chemotherapy vs placebo in second-line or later recurrent/metastatic nasopharyngeal carcinoma; currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 2, Phase 3 | Status: RECRUITING